{"ticker": {"uuid": "ee1337ad-1e5e-4325-afea-26cc3fa7e2c5", "symbol": "VALN", "name": "Valneva SE ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Behavioral Patterns of VALN and Institutional Flows", "summary": "The article analyzes Valneva SE (NASDAQ: VALN), noting a near-term weak sentiment that may lead to long-term weakness, despite a neutral shift. It highlights an exceptional 182.0:1 risk-reward setup targeting a 39.2% gain versus a 0.2% risk. The analysis also provides specific in", "url": "https://news.stocktradersdaily.com/news_release/8/Behavioral_Patterns_of_VALN_and_Institutional_Flows_071426121202_1784002322.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-14T00:12:00", "published_display": "14 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ixiaro by Valneva SE - Japanese encephalitis shot for serious travelers", "summary": "This article provides an in-depth look at Ixiaro, Valneva's inactivated Japanese encephalitis vaccine. It details the vaccine's target demographic, dosing schedule, safety profile, regulatory approvals, and its strategic position within Valneva's vaccine portfolio. The article al", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/ixiaro-by-valneva-se-japanese-encephalitis-shot-for-serious-travelers/69741708", "source_name": "ad-hoc-news.de", "published_at": "2026-07-11T06:39:45", "published_display": "11 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Valneva SE Stocks", "summary": "This article lists several ETFs that hold Valneva SE stocks, providing information such as market value, weight, issuer, management style, focus, expense ratio, AUM, price change, relative volume, and 3-year NAV total return for each ETF. The ETFs primarily focus on genomics, imm", "url": "https://www.tradingview.com/symbols/LSX-A0MVJZ/etfs/", "source_name": "TradingView", "published_at": "2026-07-08T19:39:26", "published_display": "08 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Ixiaro vaccine - Valneva bets on niche travel protection", "summary": "Valneva's Ixiaro vaccine targets travelers and military personnel at risk of Japanese encephalitis in Asia-Pacific regions. The article details the vaccine's design, efficacy, market positioning, and regulatory approvals, emphasizing its role within Valneva's specialized travel v", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/the-ixiaro-vaccine-valneva-bets-on-niche-travel-protection/69723893", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T15:03:00", "published_display": "08 Jul 2026 15:03", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Valneva SE \u2013 EURONEXT:VLA", "summary": "This page provides financial information for Valneva SE (EURONEXT:VLA), specifically focusing on its forward price-to-earnings ratio. The content is presented within the TradingView platform, noting that the market was closed and no trades were made at the time of viewing. It app", "url": "https://www.tradingview.com/symbols/EURONEXT-VLA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T21:10:08", "published_display": "04 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(VALN) Movement Within Algorithmic Entry Frameworks", "summary": "The article analyzes Valneva SE (NASDAQ: VALN) using algorithmic entry frameworks. It notes stable neutral readings in shorter horizons, potentially easing a long-term weak bias, and highlights an exceptional 192.0:1 risk-reward setup targeting a 39.6% gain. Three distinct tradin", "url": "https://news.stocktradersdaily.com/news_release/10/VALN_Movement_Within_Algorithmic_Entry_Frameworks_070226110402_1783047842.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T23:04:00", "published_display": "02 Jul 2026 23:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Valneva SE (VALN) purchasers following a significant drop in its American Depositary Receipt (ADR) price. This decline occurred after Valneva and Pfizer announced topline results from their Phase 3 ", "url": "https://www.natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-valneva-se-valn-and-encourages", "source_name": "The National Law Review", "published_at": "2026-07-02T08:09:14", "published_display": "02 Jul 2026 08:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Valneva SE (NASDAQ: VALN) after its American Depositary Receipt (ADR) price dropped significantly following the announcement of Phase 3 clinical trial results for its Lyme disease vaccine candidate. The ", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-valneva-se-valn-and-1", "source_name": "The National Law Review", "published_at": "2026-06-30T15:09:05", "published_display": "30 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AYJ0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides the forecast and price target for Valneva SE Sponsored ADR (AYJ0) on the Frankfurt Stock Exchange. Based on 10 analysts' 1-year price forecasts, the price target is 11.28. The article also touches on EPS and revenue metrics, alongside a disclaimer about inve", "url": "https://www.tradingview.com/symbols/FWB-AYJ0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-30T06:40:49", "published_display": "30 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Ordinary Shares of Valneva SE are subject to a Lock-Up Agreement Ending on 30-JUN-2026.", "summary": "Certain ordinary shares of Valneva SE are under a lock-up agreement set to end on June 30, 2026. The lock-up period for these shares is 61 days, starting from April 30, 2026, and applies to the company\u2019s board members and executive officers in connection with a Reserved Offering.", "url": "https://www.marketscreener.com/news/certain-ordinary-shares-of-valneva-se-are-subject-to-a-lock-up-agreement-ending-on-30-jun-2026-ce7f5fdfdf8ef625", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T00:40:49", "published_display": "30 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Shareholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Valneva SE (NASDAQ:VALN) on behalf of investors. This investigation follows a significant drop in Valneva's ADR price after its Lyme disease vaccine candidate, developed with Pfizer, failed to meet its p", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-valneva-se-valn-and-0", "source_name": "The National Law Review", "published_at": "2026-06-28T14:09:58", "published_display": "28 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A3CPD1 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This page provides a forecast and price target for Valneva SE Sponsored ADR (A3CPD1) for 2027. Ten analysts have provided 1-year price forecasts, although the maximum and minimum estimates are not displayed. The page also touches on analyst ratings, EPS, and revenue metrics.", "url": "https://www.tradingview.com/symbols/LS-A3CPD1/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T22:41:47", "published_display": "27 Jun 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VLA: Travel Vaccine Headwinds Will Set Up Future Repricing Potential", "summary": "Analysts have reduced their fair value estimate for Valneva (VLA) by 25% to \u20ac5.23 per share, primarily due to updated assumptions for discount rate, revenue growth, profit margin, and future P/E levels. This adjustment comes amidst Valneva lowering its 2026 earnings and sales gui", "url": "https://simplywall.st/community/narratives/fr/pharmaceuticals-biotech/epa-vla/valneva-shares/hprmqrou-rapid-lyme-vaccine-development-and-rising-preventative-healthcare-will-shape-future-markets-yh99/updates/6-analysts-have-cut-their-fair-value-estimate-for-valneva-from", "source_name": "Simply Wall Street", "published_at": "2026-06-27T18:09:58", "published_display": "27 Jun 2026 18:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE Sponsored ADR Actuals & Estimates (NASDAQ:VALN)", "summary": "This page provides financial actuals and estimates for Valneva SE (NASDAQ:VALN), allowing users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. It highlights the ability to compare actual results with average, hi", "url": "https://www.tradingview.com/symbols/NASDAQ-VALN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:10:18", "published_display": "26 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE (VALN) Shareholder/Analyst Call - Slideshow (NASDAQ:VALN)", "summary": "This article announces that Valneva SE (VALN) published a slide deck in conjunction with a shareholder/analyst call. The content is primarily a placeholder for the accompanying slideshow, indicating that further details would be found within the provided slides. The article was w", "url": "https://seekingalpha.com/article/4917923-valneva-se-valn-shareholder-analyst-call-slideshow", "source_name": "Seeking Alpha", "published_at": "2026-06-26T05:10:18", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VALN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a brief forecast for Valneva SE (VALN), including its price target and analyst ratings. Based on 10 analysts, the 1-year price forecast is $12.88. The article also touches upon EPS and revenue metrics, advising that the content is not investment advice.", "url": "https://www.tradingview.com/symbols/NASDAQ-VALN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T03:41:09", "published_display": "26 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Valneva Announces Successful Outcome of Its Annual General Meeting", "summary": "Valneva SE announced the successful outcome of its Annual General Meeting held on June 28, 2024, in Lyon, France. Shareholders approved all proposed resolutions, including the re-election of Deloitte & Associ\u00e9s as statutory auditor, the appointment of a new independent director, ", "url": "https://www.moomoo.com/news/post/72047978/press-release-valneva-announces-successful-outcome-of-its-annual-general", "source_name": "Moomoo", "published_at": "2026-06-25T18:09:58", "published_display": "25 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva Announces Successful Outcome of its Annual General Meeting", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/valneva-announces-successful-outcome-annual-154500337.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T15:45:00+00:00", "published_display": "25 Jun 2026 15:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VLA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Valneva SE (VLA) stock, based on analysis from 10 financial analysts. It details the company's current stock price, recent performance trends, and financial metrics such as earnings per share, revenue, and market capitalizatio", "url": "https://www.tradingview.com/symbols/EURONEXT-VLA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:41:09", "published_display": "25 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva (Nasdaq: VALN) holders approve AGM items and elect new chair", "summary": "Valneva SE shareholders approved all Board-recommended resolutions at its Annual General Meeting, including the 2025 financial statements and the transfer of its registered office to Lyon. Dr. Gerd Zettlmeissl was appointed as the new Chair of the Board of Directors, succeeding A", "url": "https://www.stocktitan.net/sec-filings/VALN/6-k-valneva-se-current-report-foreign-issuer-fd1713785b1e.html", "source_name": "Stock Titan", "published_at": "2026-06-25T15:40:39", "published_display": "25 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE (VALN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Valneva SE (VALN) has a financial score of 7.31, ranking 127 out of 387 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue decreased by 34.74% year-over-year to $36.30M, and it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-valn/financial-health", "source_name": "TradingKey", "published_at": "2026-06-25T10:40:39", "published_display": "25 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Valneva SE \u2013 OTC:INRLF", "summary": "This page from TradingView displays \"Price to earnings forward\" data for Valneva SE (OTC: INRLF). The content is primarily a navigation-heavy interface for financial data, indicating that the specific financial metric for Valneva SE is accessible through this platform. The curren", "url": "https://www.tradingview.com/symbols/OTC-INRLF/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T08:40:39", "published_display": "25 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (VALN) Movements Inform Risk Allocation Models", "summary": "This article analyzes Valneva Se (VALN) stock movements, suggesting that strong near-term sentiment might challenge persistent mid and long-term weakness. It highlights an exceptional risk-reward setup targeting a 38.8% gain and outlines three AI-generated trading strategies with", "url": "https://news.stocktradersdaily.com/news_release/11/How_VALN_Movements_Inform_Risk_Allocation_Models_062126095202_1782093122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T21:52:00", "published_display": "21 Jun 2026 21:52", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva\u2019s Credibility Test: Stock Near Lows as Lyme Vaccine Data Gives Conflicting Signals", "summary": "Valneva's stock is near its 52-week low, battered by conflicting data from its Lyme vaccine candidate, LB6V, developed with Pfizer, which failed its primary statistical endpoint in a Phase 3 study. The company is facing a skeptical shareholder base ahead of its annual general mee", "url": "https://www.aktiencheck.de/news/Artikel-Valneva_s_Credibility_Test_Stock_Near_Lows_as_Lyme_Vaccine_Data_Gives_Conflicting_Signals-19866959", "source_name": "aktiencheck.de", "published_at": "2026-06-20T12:39:00", "published_display": "20 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE (VALN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a detailed timeline of Valneva SE's (VALN) dividend history and stock split events. It indicates that Valneva SE has not distributed any dividends over the past five years and has no recorded stock splits. The page serves as a financial data reference from Tr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-valn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T13:40:52", "published_display": "18 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE (VALN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Valneva SE (VALN) based on its business segments and regional contributions. As of April 6, the company's main revenue drivers are IXIARO and DUKORAL, with significant contributions from the United States and Canada. The data", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-valn/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T02:39:49", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE (VALN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Valneva SE (VALN) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have an average price target of $13.00 for VALN, with a majority recommending a \"Buy\" rating. The company's expected revenue for the next quarter ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-valn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T12:10:37", "published_display": "17 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Valneva SE SEC Filing", "summary": "This article reports on Valneva SE's SEC filing of Form EFFECT, indicating the effectiveness of their F-3 registration statement. The filing, dated June 16, 2026, involves the company Valneva SE (NASDAQ: VALN) and provides details regarding its market capitalization, industry, an", "url": "https://www.stocktitan.net/sec-filings/VALN/effect-valneva-se-sec-filing-d3fdb9554dde.html", "source_name": "Stock Titan", "published_at": "2026-06-17T10:10:39", "published_display": "17 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protective clarity for your vaccine shares with the Valneva SE investor focus", "summary": "This article provides an investor focus on Valneva SE (ISIN FR0013280286), a company specializing in prophylactic vaccines. It offers shareholders a concise overview of the company's stock context, pipeline, and how to track relevant news and financial data. The article emphasize", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/protective-clarity-for-your-vaccine-shares-with-the-valneva-se-investor/69558581", "source_name": "AD HOC NEWS", "published_at": "2026-06-17T03:10:39", "published_display": "17 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE - Files For Offer And Resale From Time To Time By Selling Securityholders Of Up 31.6 Million Ordinary Shares", "summary": "Valneva SE has filed for an offer and resale of up to 31.6 million ordinary shares by its selling securityholders. The news, reported by Reuters and sourced from Refinitiv, indicates a significant potential change in the company's share structure. This development is relevant for", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42O0K8:0-valneva-se-files-for-offer-and-resale-from-time-to-time-by-selling-securityholders-of-up-31-6-million-ordinary-shares/", "source_name": "TradingView", "published_at": "2026-06-16T21:08:59", "published_display": "16 Jun 2026 21:08", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE (NASDAQ: VALN) registers 31.6M resale shares, warrants included", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNS0JsWHl4cWJPWFVsZ09CSEI2a3pYWktyeUh0Q0hYdWxFTU5WOHN0VTBRWFJZVUdFeW5DS3R0Ykk2M1JBY2M0LUNXNzZrY3BYQ0V1TlJKNDFHc2hpV1pId0NXZGpfdEw2ekF3TFllY3RIb3ZyVm9vNGJTMUE3bDJ6TUNUZVg5N1ZtZGdVMllvQVU2cFZXTmRZMlhJR1MyYVYxMXRvb2pNZUpoWWdYY0NoNTl2NzZfYUVuZ0JUSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva Publishes Documentation for June 25, 2026 Annual General Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOczhwNnpOdWZWUEZWbkhYVHZCVlpHOUFfX1hsaGlUMHJtTkFkcmhiWU83Z3Z6Q0VqWTY4QzhLdzlmTUo3cm16RkxNQjQ4TzgtMDZ6MlU0ZC1BaDJpVlpTVVd5X3RTSXpqRXRjcU1fQTVoanJhZTdNMW1yT0NhNHdRS1I4TWt2NHdvRWRjM1pRMll2aDZMWDBuQ3l0SjZmei0zXy0tN3ktUXRET1M3QTdDWmlnMkx6YWNuemVINVA3TlVHR0NaTXVpeTFYUnE2UGJ0VWhDOUZfd0FsY1ZmU1dnNmE3T0VsM1FlNXh4QQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva (NASDAQ: VALN) details access to 2026 Annual General Meeting documents", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZHlCMktuMGNlem9HTWZidWRMSDRFYW9TSlJuT3g0c3o0S05CSl9pZk1iSnhSU1VvQnJScFpTNTJLSHpwRVRIY1pIQ3BRcEZkQTVUMi1fSU9MNnY5djVDQU5Cbi1HUnNxcFpzandPRmZsYm4wX0UzSFZXdXd6Q0ZHajFhMGJYV3FBSTZWWnhIX1RDQS00VFduVVVMS2NtMUpIYXVuTTl4YmFXdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva Announces Availability of Documentation for its Annual General Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/valneva-announces-availability-documentation-annual-050000939.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T05:00:00+00:00", "published_display": "04 Jun 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/valneva-declaration-shares-voting-rights-160000347.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T16:00:00+00:00", "published_display": "03 Jun 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Valneva Se (VALN) Affects Rotational Strategy Timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQb1ZBa0VnZkJFN29sTFRBejJlMjhhaTRrN2haVElTTGpadEVJdk1fOXRnUmItbkJoZDBnMWZoRUZGWVozcXAzNWpmS2tGZVRsMExEZko0SmdHZkNCdVp1dXV1R28wMFMyeHRKQUl0X1lSSmNEUkktV0xkSlVFZHJ0YkZDVEg0dTZEb1NEYW9xbERxYWw3Qm9rUUlzMTJmSVBULWp1X1NDLXBqd1VVcXkxdDVDUGlMUDJfb2U0Y1Y2U1diUG5XRzl1OGJNVW40Zw?oc=5", "source_name": "Stock Traders Daily", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva to Participate at U.S. and European Investor Conferences in June", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/valneva-participate-u-european-investor-154500213.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T15:45:00+00:00", "published_display": "28 May 2026 15:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva (VALN) Gets a Buy from H.C. Wainwright", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOQ0ZFaHhOaXZFTzk4SUFlSFIxWVp2QWM1UjlBZlh0NktEUy1ZZ3U3NTZhU2dDNnNTd1RLQTYxT0VwTnprZ3hueTFGRU9hV3JTZWo1ajVSSjVtQ1JCa1J0dm42ZnVXSm40V3JLOUh2ckZPWjc1dWJQUnhHQlpVT2U4bDBjX0ZEdVJoZ2hGSGhSYkxHNmxWMEZ0T3A0djFLS3ZFOXhnMjE4Q1ZFbVd0X2ZnMm56b3pLLXdnem5ob1k3ZFFTRlRpaVE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Valneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/valneva-se-inrlf-q1-2026-230018488.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T23:00:18+00:00", "published_display": "13 May 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/ef71a0e2-873d-356e-9ffb-b451c4b1ec8b/valneva-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-13T19:10:56+00:00", "published_display": "13 May 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript: Valneva Q1 2026 Earnings Conference Call", "summary": "", "url": "https://finance.yahoo.com/news/transcript-valneva-q1-2026-earnings-155143868.html", "source_name": "Benzinga", "published_at": "2026-05-13T15:51:43+00:00", "published_display": "13 May 2026 15:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPMVhJNWNQbi1WbjNnZVR3UVBrdTY0eVdTQ2tZWmJ1YlRWM2doWjAxb0owX3JTUFA3TFE3T05VU3Y5R2VOX1BVWVZfVjV6S0JsTHlHVlhQR1VaQkN4d0h3N0JmTnJfSWllWGRNek5NMGQyNFBKcldyTV9HYTJSMzEzWkxKNndMU1BFclZFbnd2dkZEaUZFaUk0aE5GWUJCNlFVSTNzSFk2QVZTWDRnUXp3dlZWOGVoenFaa1ByZUVUZDBKUENHX2xOWVo1NVdISDQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates", "summary": "", "url": "https://finance.yahoo.com/news/valneva-reports-first-quarter-2026-050000493.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T05:00:00+00:00", "published_display": "13 May 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Valneva to Report First Quarter 2026 Consolidated Financial Results\u00a0on May 13, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/valneva-report-first-quarter-2026-093600448.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T09:36:00+00:00", "published_display": "06 May 2026 09:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva (VALN) schedules Q1 2026 results webcast for May 13", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOMXNqdG5wTzluTUpiZDFLbjI1T3FFYmpUdVZqQjJOTXZoZV8zQnJFdTJIVmk5U19HRjlaNEVIV0NDWE9nYUF1RHRwM2xvNEF6c0x6OUxZUV9aR3R5QWR6U0lMTXk3ZV9WYTczVzNSckFBR2tUbFN3ZGlYYmcxWWRaRjhrOVBXOW9Xc1MwVS1MUTlMWVBCT3ByQ0Jfb0Y1NHpVc0FVeUpOX3oyZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Goldman Sachs downgrades Valneva stock rating to sell on Lyme vaccine uncertainty", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNeTFqSGJaVUxYYnBVemNCZ1hzRkdWMEVrWC1QMjBxRTZSaVdpcllzaHlRMDhOS2taSm9VMzk3R3BVUTVERXFkVE5yWFNva28tUDZuc1JLZGpRZWt0dHJXdWxHek5FVk82cHJxeU5MSGpZdlRQN1h2UEJ4cmMyMzJiMlRubjg5N0xadHc2djlMckJTR0pnejgtQmNhejNOYkpPakJobU1LaWljRFU3UzdseE1oUG94eUdwRkVubGJ4aWV6UXBJM3hWRjRmaHJWUk5pYVFMbEUxUzM?oc=5", "source_name": "Investing.com", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOWVUyTVFQVlZ4SExuRXI3X3VLak9RdzAteXhEdEt0SUF1djVOdzZpNF9TQzlENGZBcmlUQVVXQ1NVbXh1cllLVE9lS0N0c01KMl9CSUdDRXhETF9UNlZYMTNsUVF5V2ZUdUh6MHVCQkRVWXFHdk5BZnhVc0pqcFV4bmlWOGhfSVpMX1NsbndyeUtPTUdGSXgzek94bWRVbEk?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Reiterates Buy Rating on Valneva (VALN) After Phase 3 Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOTC0tN01VV3VmbTJxMi1xUnF5VjRFTlU0aEhPbGluQkxpZThITFB5dzhUYUdaazREMjFISDI2ajBlYVcyVTlmTkYzUFhNMl9JTlZnbnlNaEJXX2dQUnBvcEFJa1BLNTYwN3lIZ0tjR3FVaEU3dm1CNFV4UUhObUR1N2hheElPLXJMem96cVhBNHd5SERJYUE5M0FfU0wwSllOX192MXpkcW5pbFd3?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Valneva Se (VALN) Risk Zones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQcUtNZXZQMUFqMTB0NW9IZ3ZjR2x3enZKRFdFODNVNzRnUnNYZzkxbEdjSW8tU0pXdU16V1QxLWoxQzg5Y3o4MjM4ZnJSclhXWE5USzJEVU4yMVp3Y0ZqSEhDcnZEZm1zaVNoamN3ZFM5ZWFQY19uY08yMENoLWNkOFY3VTNXVXgwZHpuS2NDS0lXeUdDTi0zODZTR0QycTVLTnI5NC10d1dvQk5sUnpwTjFVRl9mVk5vOHRZUGVNYmY2Q1dKVFlDaQ?oc=5", "source_name": "Stock Traders Daily", "published_at": "2026-04-05T07:00:00+00:00", "published_display": "05 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Valneva stock falls after withdrawing chikungunya vaccine BLA in U.S. By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQTVROU3Jzb3htSjliSWR2cjdxRDdTN3d2RmlQUDl2aUExREJNZXFlYkJtVE5XTWhsRWV0S1RROW5Qd0NpMlpXTUlJNmc1aHc2WXdqM004YTRReWhMd0paR3dMYzdNVUlwSVYyQ1hwck1uSFZtd0sxZ3dGQkRxSG1WSlV6NXBwR0NYVGZGWWdlYW1KaUhxbzMyQWRvd3p6Y1NwTG1lTFRfek1XNHk4NFFYSm5uZElRWnkwa3VwMDhfVE9yU0pzLUhR?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VALN: Valneva SE - ADR Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTFAzMS1yMzFfUEVYZ0Ztd09NcTBESGoyVEtOY3lzRkhMSXJHLVhCNEp5RndfNUVvOFlGOE9uSzJ6QVNnUkhWenZDN1l3?oc=5", "source_name": "Stocktwits", "published_at": "2021-05-16T16:02:38+00:00", "published_display": "16 May 2021 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Behavioral Patterns of VALN and Institutional Flows", "summary": "The article analyzes Valneva SE (NASDAQ: VALN), noting a near-term weak sentiment that may lead to long-term weakness, despite a neutral shift. It highlights an exceptional 182.0:1 risk-reward setup targeting a 39.2% gain versus a 0.2% risk. The analysis also provides specific in", "url": "https://news.stocktradersdaily.com/news_release/8/Behavioral_Patterns_of_VALN_and_Institutional_Flows_071426121202_1784002322.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-14T00:12:00", "published_display": "14 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ixiaro by Valneva SE - Japanese encephalitis shot for serious travelers", "summary": "This article provides an in-depth look at Ixiaro, Valneva's inactivated Japanese encephalitis vaccine. It details the vaccine's target demographic, dosing schedule, safety profile, regulatory approvals, and its strategic position within Valneva's vaccine portfolio. The article al", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/ixiaro-by-valneva-se-japanese-encephalitis-shot-for-serious-travelers/69741708", "source_name": "ad-hoc-news.de", "published_at": "2026-07-11T06:39:45", "published_display": "11 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Valneva SE Stocks", "summary": "This article lists several ETFs that hold Valneva SE stocks, providing information such as market value, weight, issuer, management style, focus, expense ratio, AUM, price change, relative volume, and 3-year NAV total return for each ETF. The ETFs primarily focus on genomics, imm", "url": "https://www.tradingview.com/symbols/LSX-A0MVJZ/etfs/", "source_name": "TradingView", "published_at": "2026-07-08T19:39:26", "published_display": "08 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Ixiaro vaccine - Valneva bets on niche travel protection", "summary": "Valneva's Ixiaro vaccine targets travelers and military personnel at risk of Japanese encephalitis in Asia-Pacific regions. The article details the vaccine's design, efficacy, market positioning, and regulatory approvals, emphasizing its role within Valneva's specialized travel v", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/the-ixiaro-vaccine-valneva-bets-on-niche-travel-protection/69723893", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T15:03:00", "published_display": "08 Jul 2026 15:03", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Valneva SE \u2013 EURONEXT:VLA", "summary": "This page provides financial information for Valneva SE (EURONEXT:VLA), specifically focusing on its forward price-to-earnings ratio. The content is presented within the TradingView platform, noting that the market was closed and no trades were made at the time of viewing. It app", "url": "https://www.tradingview.com/symbols/EURONEXT-VLA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T21:10:08", "published_display": "04 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(VALN) Movement Within Algorithmic Entry Frameworks", "summary": "The article analyzes Valneva SE (NASDAQ: VALN) using algorithmic entry frameworks. It notes stable neutral readings in shorter horizons, potentially easing a long-term weak bias, and highlights an exceptional 192.0:1 risk-reward setup targeting a 39.6% gain. Three distinct tradin", "url": "https://news.stocktradersdaily.com/news_release/10/VALN_Movement_Within_Algorithmic_Entry_Frameworks_070226110402_1783047842.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T23:04:00", "published_display": "02 Jul 2026 23:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Valneva SE (VALN) purchasers following a significant drop in its American Depositary Receipt (ADR) price. This decline occurred after Valneva and Pfizer announced topline results from their Phase 3 ", "url": "https://www.natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-valneva-se-valn-and-encourages", "source_name": "The National Law Review", "published_at": "2026-07-02T08:09:14", "published_display": "02 Jul 2026 08:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Valneva SE (NASDAQ: VALN) after its American Depositary Receipt (ADR) price dropped significantly following the announcement of Phase 3 clinical trial results for its Lyme disease vaccine candidate. The ", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-valneva-se-valn-and-1", "source_name": "The National Law Review", "published_at": "2026-06-30T15:09:05", "published_display": "30 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AYJ0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides the forecast and price target for Valneva SE Sponsored ADR (AYJ0) on the Frankfurt Stock Exchange. Based on 10 analysts' 1-year price forecasts, the price target is 11.28. The article also touches on EPS and revenue metrics, alongside a disclaimer about inve", "url": "https://www.tradingview.com/symbols/FWB-AYJ0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-30T06:40:49", "published_display": "30 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Ordinary Shares of Valneva SE are subject to a Lock-Up Agreement Ending on 30-JUN-2026.", "summary": "Certain ordinary shares of Valneva SE are under a lock-up agreement set to end on June 30, 2026. The lock-up period for these shares is 61 days, starting from April 30, 2026, and applies to the company\u2019s board members and executive officers in connection with a Reserved Offering.", "url": "https://www.marketscreener.com/news/certain-ordinary-shares-of-valneva-se-are-subject-to-a-lock-up-agreement-ending-on-30-jun-2026-ce7f5fdfdf8ef625", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T00:40:49", "published_display": "30 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Shareholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Valneva SE (NASDAQ:VALN) on behalf of investors. This investigation follows a significant drop in Valneva's ADR price after its Lyme disease vaccine candidate, developed with Pfizer, failed to meet its p", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-valneva-se-valn-and-0", "source_name": "The National Law Review", "published_at": "2026-06-28T14:09:58", "published_display": "28 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A3CPD1 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This page provides a forecast and price target for Valneva SE Sponsored ADR (A3CPD1) for 2027. Ten analysts have provided 1-year price forecasts, although the maximum and minimum estimates are not displayed. The page also touches on analyst ratings, EPS, and revenue metrics.", "url": "https://www.tradingview.com/symbols/LS-A3CPD1/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T22:41:47", "published_display": "27 Jun 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VLA: Travel Vaccine Headwinds Will Set Up Future Repricing Potential", "summary": "Analysts have reduced their fair value estimate for Valneva (VLA) by 25% to \u20ac5.23 per share, primarily due to updated assumptions for discount rate, revenue growth, profit margin, and future P/E levels. This adjustment comes amidst Valneva lowering its 2026 earnings and sales gui", "url": "https://simplywall.st/community/narratives/fr/pharmaceuticals-biotech/epa-vla/valneva-shares/hprmqrou-rapid-lyme-vaccine-development-and-rising-preventative-healthcare-will-shape-future-markets-yh99/updates/6-analysts-have-cut-their-fair-value-estimate-for-valneva-from", "source_name": "Simply Wall Street", "published_at": "2026-06-27T18:09:58", "published_display": "27 Jun 2026 18:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE Sponsored ADR Actuals & Estimates (NASDAQ:VALN)", "summary": "This page provides financial actuals and estimates for Valneva SE (NASDAQ:VALN), allowing users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. It highlights the ability to compare actual results with average, hi", "url": "https://www.tradingview.com/symbols/NASDAQ-VALN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:10:18", "published_display": "26 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE (VALN) Shareholder/Analyst Call - Slideshow (NASDAQ:VALN)", "summary": "This article announces that Valneva SE (VALN) published a slide deck in conjunction with a shareholder/analyst call. The content is primarily a placeholder for the accompanying slideshow, indicating that further details would be found within the provided slides. The article was w", "url": "https://seekingalpha.com/article/4917923-valneva-se-valn-shareholder-analyst-call-slideshow", "source_name": "Seeking Alpha", "published_at": "2026-06-26T05:10:18", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VALN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a brief forecast for Valneva SE (VALN), including its price target and analyst ratings. Based on 10 analysts, the 1-year price forecast is $12.88. The article also touches upon EPS and revenue metrics, advising that the content is not investment advice.", "url": "https://www.tradingview.com/symbols/NASDAQ-VALN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T03:41:09", "published_display": "26 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Valneva Announces Successful Outcome of Its Annual General Meeting", "summary": "Valneva SE announced the successful outcome of its Annual General Meeting held on June 28, 2024, in Lyon, France. Shareholders approved all proposed resolutions, including the re-election of Deloitte & Associ\u00e9s as statutory auditor, the appointment of a new independent director, ", "url": "https://www.moomoo.com/news/post/72047978/press-release-valneva-announces-successful-outcome-of-its-annual-general", "source_name": "Moomoo", "published_at": "2026-06-25T18:09:58", "published_display": "25 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva Announces Successful Outcome of its Annual General Meeting", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/valneva-announces-successful-outcome-annual-154500337.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T15:45:00+00:00", "published_display": "25 Jun 2026 15:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VLA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Valneva SE (VLA) stock, based on analysis from 10 financial analysts. It details the company's current stock price, recent performance trends, and financial metrics such as earnings per share, revenue, and market capitalizatio", "url": "https://www.tradingview.com/symbols/EURONEXT-VLA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:41:09", "published_display": "25 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva (Nasdaq: VALN) holders approve AGM items and elect new chair", "summary": "Valneva SE shareholders approved all Board-recommended resolutions at its Annual General Meeting, including the 2025 financial statements and the transfer of its registered office to Lyon. Dr. Gerd Zettlmeissl was appointed as the new Chair of the Board of Directors, succeeding A", "url": "https://www.stocktitan.net/sec-filings/VALN/6-k-valneva-se-current-report-foreign-issuer-fd1713785b1e.html", "source_name": "Stock Titan", "published_at": "2026-06-25T15:40:39", "published_display": "25 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE (VALN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Valneva SE (VALN) has a financial score of 7.31, ranking 127 out of 387 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue decreased by 34.74% year-over-year to $36.30M, and it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-valn/financial-health", "source_name": "TradingKey", "published_at": "2026-06-25T10:40:39", "published_display": "25 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Valneva SE \u2013 OTC:INRLF", "summary": "This page from TradingView displays \"Price to earnings forward\" data for Valneva SE (OTC: INRLF). The content is primarily a navigation-heavy interface for financial data, indicating that the specific financial metric for Valneva SE is accessible through this platform. The curren", "url": "https://www.tradingview.com/symbols/OTC-INRLF/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T08:40:39", "published_display": "25 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (VALN) Movements Inform Risk Allocation Models", "summary": "This article analyzes Valneva Se (VALN) stock movements, suggesting that strong near-term sentiment might challenge persistent mid and long-term weakness. It highlights an exceptional risk-reward setup targeting a 38.8% gain and outlines three AI-generated trading strategies with", "url": "https://news.stocktradersdaily.com/news_release/11/How_VALN_Movements_Inform_Risk_Allocation_Models_062126095202_1782093122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T21:52:00", "published_display": "21 Jun 2026 21:52", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva\u2019s Credibility Test: Stock Near Lows as Lyme Vaccine Data Gives Conflicting Signals", "summary": "Valneva's stock is near its 52-week low, battered by conflicting data from its Lyme vaccine candidate, LB6V, developed with Pfizer, which failed its primary statistical endpoint in a Phase 3 study. The company is facing a skeptical shareholder base ahead of its annual general mee", "url": "https://www.aktiencheck.de/news/Artikel-Valneva_s_Credibility_Test_Stock_Near_Lows_as_Lyme_Vaccine_Data_Gives_Conflicting_Signals-19866959", "source_name": "aktiencheck.de", "published_at": "2026-06-20T12:39:00", "published_display": "20 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE (VALN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a detailed timeline of Valneva SE's (VALN) dividend history and stock split events. It indicates that Valneva SE has not distributed any dividends over the past five years and has no recorded stock splits. The page serves as a financial data reference from Tr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-valn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T13:40:52", "published_display": "18 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE (VALN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Valneva SE (VALN) based on its business segments and regional contributions. As of April 6, the company's main revenue drivers are IXIARO and DUKORAL, with significant contributions from the United States and Canada. The data", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-valn/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T02:39:49", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE (VALN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Valneva SE (VALN) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have an average price target of $13.00 for VALN, with a majority recommending a \"Buy\" rating. The company's expected revenue for the next quarter ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-valn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T12:10:37", "published_display": "17 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Valneva SE SEC Filing", "summary": "This article reports on Valneva SE's SEC filing of Form EFFECT, indicating the effectiveness of their F-3 registration statement. The filing, dated June 16, 2026, involves the company Valneva SE (NASDAQ: VALN) and provides details regarding its market capitalization, industry, an", "url": "https://www.stocktitan.net/sec-filings/VALN/effect-valneva-se-sec-filing-d3fdb9554dde.html", "source_name": "Stock Titan", "published_at": "2026-06-17T10:10:39", "published_display": "17 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protective clarity for your vaccine shares with the Valneva SE investor focus", "summary": "This article provides an investor focus on Valneva SE (ISIN FR0013280286), a company specializing in prophylactic vaccines. It offers shareholders a concise overview of the company's stock context, pipeline, and how to track relevant news and financial data. The article emphasize", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/protective-clarity-for-your-vaccine-shares-with-the-valneva-se-investor/69558581", "source_name": "AD HOC NEWS", "published_at": "2026-06-17T03:10:39", "published_display": "17 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE - Files For Offer And Resale From Time To Time By Selling Securityholders Of Up 31.6 Million Ordinary Shares", "summary": "Valneva SE has filed for an offer and resale of up to 31.6 million ordinary shares by its selling securityholders. The news, reported by Reuters and sourced from Refinitiv, indicates a significant potential change in the company's share structure. This development is relevant for", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42O0K8:0-valneva-se-files-for-offer-and-resale-from-time-to-time-by-selling-securityholders-of-up-31-6-million-ordinary-shares/", "source_name": "TradingView", "published_at": "2026-06-16T21:08:59", "published_display": "16 Jun 2026 21:08", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE (NASDAQ: VALN) registers 31.6M resale shares, warrants included", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNS0JsWHl4cWJPWFVsZ09CSEI2a3pYWktyeUh0Q0hYdWxFTU5WOHN0VTBRWFJZVUdFeW5DS3R0Ykk2M1JBY2M0LUNXNzZrY3BYQ0V1TlJKNDFHc2hpV1pId0NXZGpfdEw2ekF3TFllY3RIb3ZyVm9vNGJTMUE3bDJ6TUNUZVg5N1ZtZGdVMllvQVU2cFZXTmRZMlhJR1MyYVYxMXRvb2pNZUpoWWdYY0NoNTl2NzZfYUVuZ0JUSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva Publishes Documentation for June 25, 2026 Annual General Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOczhwNnpOdWZWUEZWbkhYVHZCVlpHOUFfX1hsaGlUMHJtTkFkcmhiWU83Z3Z6Q0VqWTY4QzhLdzlmTUo3cm16RkxNQjQ4TzgtMDZ6MlU0ZC1BaDJpVlpTVVd5X3RTSXpqRXRjcU1fQTVoanJhZTdNMW1yT0NhNHdRS1I4TWt2NHdvRWRjM1pRMll2aDZMWDBuQ3l0SjZmei0zXy0tN3ktUXRET1M3QTdDWmlnMkx6YWNuemVINVA3TlVHR0NaTXVpeTFYUnE2UGJ0VWhDOUZfd0FsY1ZmU1dnNmE3T0VsM1FlNXh4QQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva (NASDAQ: VALN) details access to 2026 Annual General Meeting documents", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZHlCMktuMGNlem9HTWZidWRMSDRFYW9TSlJuT3g0c3o0S05CSl9pZk1iSnhSU1VvQnJScFpTNTJLSHpwRVRIY1pIQ3BRcEZkQTVUMi1fSU9MNnY5djVDQU5Cbi1HUnNxcFpzandPRmZsYm4wX0UzSFZXdXd6Q0ZHajFhMGJYV3FBSTZWWnhIX1RDQS00VFduVVVMS2NtMUpIYXVuTTl4YmFXdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva Announces Availability of Documentation for its Annual General Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/valneva-announces-availability-documentation-annual-050000939.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T05:00:00+00:00", "published_display": "04 Jun 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/valneva-declaration-shares-voting-rights-160000347.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T16:00:00+00:00", "published_display": "03 Jun 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Valneva Se (VALN) Affects Rotational Strategy Timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQb1ZBa0VnZkJFN29sTFRBejJlMjhhaTRrN2haVElTTGpadEVJdk1fOXRnUmItbkJoZDBnMWZoRUZGWVozcXAzNWpmS2tGZVRsMExEZko0SmdHZkNCdVp1dXV1R28wMFMyeHRKQUl0X1lSSmNEUkktV0xkSlVFZHJ0YkZDVEg0dTZEb1NEYW9xbERxYWw3Qm9rUUlzMTJmSVBULWp1X1NDLXBqd1VVcXkxdDVDUGlMUDJfb2U0Y1Y2U1diUG5XRzl1OGJNVW40Zw?oc=5", "source_name": "Stock Traders Daily", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva to Participate at U.S. and European Investor Conferences in June", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/valneva-participate-u-european-investor-154500213.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T15:45:00+00:00", "published_display": "28 May 2026 15:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva (VALN) Gets a Buy from H.C. Wainwright", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOQ0ZFaHhOaXZFTzk4SUFlSFIxWVp2QWM1UjlBZlh0NktEUy1ZZ3U3NTZhU2dDNnNTd1RLQTYxT0VwTnprZ3hueTFGRU9hV3JTZWo1ajVSSjVtQ1JCa1J0dm42ZnVXSm40V3JLOUh2ckZPWjc1dWJQUnhHQlpVT2U4bDBjX0ZEdVJoZ2hGSGhSYkxHNmxWMEZ0T3A0djFLS3ZFOXhnMjE4Q1ZFbVd0X2ZnMm56b3pLLXdnem5ob1k3ZFFTRlRpaVE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/valneva-se-inrlf-q1-2026-230018488.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T23:00:18+00:00", "published_display": "13 May 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/ef71a0e2-873d-356e-9ffb-b451c4b1ec8b/valneva-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-13T19:10:56+00:00", "published_display": "13 May 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript: Valneva Q1 2026 Earnings Conference Call", "summary": "", "url": "https://finance.yahoo.com/news/transcript-valneva-q1-2026-earnings-155143868.html", "source_name": "Benzinga", "published_at": "2026-05-13T15:51:43+00:00", "published_display": "13 May 2026 15:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPMVhJNWNQbi1WbjNnZVR3UVBrdTY0eVdTQ2tZWmJ1YlRWM2doWjAxb0owX3JTUFA3TFE3T05VU3Y5R2VOX1BVWVZfVjV6S0JsTHlHVlhQR1VaQkN4d0h3N0JmTnJfSWllWGRNek5NMGQyNFBKcldyTV9HYTJSMzEzWkxKNndMU1BFclZFbnd2dkZEaUZFaUk0aE5GWUJCNlFVSTNzSFk2QVZTWDRnUXp3dlZWOGVoenFaa1ByZUVUZDBKUENHX2xOWVo1NVdISDQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates", "summary": "", "url": "https://finance.yahoo.com/news/valneva-reports-first-quarter-2026-050000493.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T05:00:00+00:00", "published_display": "13 May 2026 05:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva to Report First Quarter 2026 Consolidated Financial Results\u00a0on May 13, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/valneva-report-first-quarter-2026-093600448.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T09:36:00+00:00", "published_display": "06 May 2026 09:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva (VALN) schedules Q1 2026 results webcast for May 13", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOMXNqdG5wTzluTUpiZDFLbjI1T3FFYmpUdVZqQjJOTXZoZV8zQnJFdTJIVmk5U19HRjlaNEVIV0NDWE9nYUF1RHRwM2xvNEF6c0x6OUxZUV9aR3R5QWR6U0lMTXk3ZV9WYTczVzNSckFBR2tUbFN3ZGlYYmcxWWRaRjhrOVBXOW9Xc1MwVS1MUTlMWVBCT3ByQ0Jfb0Y1NHpVc0FVeUpOX3oyZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs downgrades Valneva stock rating to sell on Lyme vaccine uncertainty", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNeTFqSGJaVUxYYnBVemNCZ1hzRkdWMEVrWC1QMjBxRTZSaVdpcllzaHlRMDhOS2taSm9VMzk3R3BVUTVERXFkVE5yWFNva28tUDZuc1JLZGpRZWt0dHJXdWxHek5FVk82cHJxeU5MSGpZdlRQN1h2UEJ4cmMyMzJiMlRubjg5N0xadHc2djlMckJTR0pnejgtQmNhejNOYkpPakJobU1LaWljRFU3UzdseE1oUG94eUdwRkVubGJ4aWV6UXBJM3hWRjRmaHJWUk5pYVFMbEUxUzM?oc=5", "source_name": "Investing.com", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOWVUyTVFQVlZ4SExuRXI3X3VLak9RdzAteXhEdEt0SUF1djVOdzZpNF9TQzlENGZBcmlUQVVXQ1NVbXh1cllLVE9lS0N0c01KMl9CSUdDRXhETF9UNlZYMTNsUVF5V2ZUdUh6MHVCQkRVWXFHdk5BZnhVc0pqcFV4bmlWOGhfSVpMX1NsbndyeUtPTUdGSXgzek94bWRVbEk?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Reiterates Buy Rating on Valneva (VALN) After Phase 3 Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOTC0tN01VV3VmbTJxMi1xUnF5VjRFTlU0aEhPbGluQkxpZThITFB5dzhUYUdaazREMjFISDI2ajBlYVcyVTlmTkYzUFhNMl9JTlZnbnlNaEJXX2dQUnBvcEFJa1BLNTYwN3lIZ0tjR3FVaEU3dm1CNFV4UUhObUR1N2hheElPLXJMem96cVhBNHd5SERJYUE5M0FfU0wwSllOX192MXpkcW5pbFd3?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Valneva Se (VALN) Risk Zones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQcUtNZXZQMUFqMTB0NW9IZ3ZjR2x3enZKRFdFODNVNzRnUnNYZzkxbEdjSW8tU0pXdU16V1QxLWoxQzg5Y3o4MjM4ZnJSclhXWE5USzJEVU4yMVp3Y0ZqSEhDcnZEZm1zaVNoamN3ZFM5ZWFQY19uY08yMENoLWNkOFY3VTNXVXgwZHpuS2NDS0lXeUdDTi0zODZTR0QycTVLTnI5NC10d1dvQk5sUnpwTjFVRl9mVk5vOHRZUGVNYmY2Q1dKVFlDaQ?oc=5", "source_name": "Stock Traders Daily", "published_at": "2026-04-05T07:00:00+00:00", "published_display": "05 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valneva stock falls after withdrawing chikungunya vaccine BLA in U.S. By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQTVROU3Jzb3htSjliSWR2cjdxRDdTN3d2RmlQUDl2aUExREJNZXFlYkJtVE5XTWhsRWV0S1RROW5Qd0NpMlpXTUlJNmc1aHc2WXdqM004YTRReWhMd0paR3dMYzdNVUlwSVYyQ1hwck1uSFZtd0sxZ3dGQkRxSG1WSlV6NXBwR0NYVGZGWWdlYW1KaUhxbzMyQWRvd3p6Y1NwTG1lTFRfek1XNHk4NFFYSm5uZElRWnkwa3VwMDhfVE9yU0pzLUhR?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VALN: Valneva SE - ADR Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTFAzMS1yMzFfUEVYZ0Ztd09NcTBESGoyVEtOY3lzRkhMSXJHLVhCNEp5RndfNUVvOFlGOE9uSzJ6QVNnUkhWenZDN1l3?oc=5", "source_name": "Stocktwits", "published_at": "2021-05-16T16:02:38+00:00", "published_display": "16 May 2021 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 59, "sentiment_summary": {"positive": 11, "negative": 13, "neutral": 35, "score": 50, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 76, "events": [{"event": "earnings", "label": "Earnings", "weight": 14.3, "count": 28}, {"event": "general", "label": "Market update", "weight": 13.2, "count": 24}, {"event": "analyst", "label": "Analyst action", "weight": 2.55, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 13}, "market_context": {"has_market_context": true, "latest_close": 5.05, "latest_week": "2026-07-10", "one_week_move": -3.3, "four_week_move": -5.7, "twelve_week_move": -15.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.556125, "market_dynamics_buy_signal": false, "relative_strength": -48.621226, "fair_value_gap": -38.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.7957, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.3% over one week, -5.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 10}, {"label": "Market source", "count": 7}, {"label": "GlobeNewswire", "count": 6}, {"label": "Stock Traders Daily", "count": 5}, {"label": "Stock Titan", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "The National Law Review", "count": 3}, {"label": "AD HOC NEWS", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 28}, {"label": "Market update", "count": 24}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.3% over one week, -5.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Behavioral Patterns of VALN and Institutional Flows"}], "updated_at": "2026-07-16T14:29:18.953988+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}